MONDAY, April 30, 2007 (HealthDay News) -- GlaxoSmithKline's Veramyst (fluticasone furoate) has been approved by the U.S. Food and Drug Administration to treat symptoms of seasonal and perennial allergies in people two years and older, the company said Monday.
The corticosteroid spray was particularly effective in reducing itchy, water eyes, in addition to stemming typical nasal symptoms including congestion, sneezing, and itchy and runny nose, Glaxo said in news release.
The drug was evaluated in clinical trials involving more than 2,900 adults and children. The most common adverse reactions included headache, nose bleed, and nasal sores.
The prescription spray should be available nationwide in the United States by the end of May, Glaxo said.
Visit this FDA page to learn more about the approval.